Clinical trial: cyclophosphamide pulse therapy – a promising therapeutic alternative in refractory Crohn’s disease

Background  In severe steroid‐refractory Crohn’s disease (CD), established therapies fail in a relevant proportion of patients. Recent pilot studies indicated the efficacy of cyclophosphamide pulse therapy in these patients.

[1]  K. Honey.  The comeback kid: TYSABRI now FDA approved for Crohn disease. , 2008, The Journal of clinical investigation.

[2]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[3]  S. Hanauer.  Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". , 2007, Reviews in gastroenterological disorders.

[4]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[5]  M. Zeitz,et al.  Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long‐term remission in patients with steroid‐refractory Crohn's disease , 2006, Alimentary pharmacology & therapeutics.

[6]  Z. Barta,et al.  Pulse cyclophosphamide therapy for inflammatory bowel disease. , 2006, World journal of gastroenterology.

[7]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[8]  V. Tesar,et al.  Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials. , 2006, Prague medical report.

[9]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[10]  A. Tzioufas,et al.  Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide , 2004, Lupus.

[11]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[12]  M. Zeitz,et al.  Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease , 2003, Gut.

[13]  J. Piette,et al.  Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. , 2002, The Journal of rheumatology.

[14]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[15]  A. P. Menezes,et al.  Risk factors for ovarian failure in patients with systemic lupus erythematosus. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[16]  D. Adu,et al.  The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  G. Fick,et al.  Azathioprine for maintaining remission of Crohn's disease. , 1998, The Cochrane database of systematic reviews.

[18]  Colvin Om.  An overview of cyclophosphamide development and clinical applications. , 1999 .

[19]  O. Colvin.  An overview of cyclophosphamide development and clinical applications. , 1999, Current pharmaceutical design.

[20]  M. Haubitz,et al.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. , 1998, Arthritis and rheumatism.

[21]  R. Luqmani,et al.  Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis , 1998, Clinical pharmacokinetics.

[22]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[23]  P. Leszczyński,et al.  Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. , 1994, Zeitschrift fur Rheumatologie.

[24]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[25]  I. Süveges,et al.  Vogt‐Koyanagi‐Harada syndrome , 1993, Acta ophthalmologica.

[26]  R. Glassock,et al.  Immunosuppressive drug therapy in lupus nephritis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[28]  J. Fort,et al.  Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. , 1988, Arthritis and rheumatism.

[29]  W. Mccune,et al.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. , 1988, The New England journal of medicine.

[30]  K. Ewe,et al.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.

[31]  A. Ahmed,et al.  Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. , 1984, Journal of the American Academy of Dermatology.

[32]  H. Paulus,et al.  Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. , 1974, Arthritis and rheumatism.

[33]  F. Bourseaux,et al.  Synthese und Abbau cytostatisch wirksamer cyclischer N-Phosphamidester des Bis-(β-chloräthyl)-amins , 1958 .

[34]  J. L. Fahey,et al.  Wegener's granulomatosis. , 1954, The American journal of medicine.